Search clinical trials for: Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)

Total 132 results

Bayer

Completed

A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema (DRAKO)

Macular Edema

United Kingdom
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

United States, Spain, Korea, Republic of, Czechia, Japan, Singapore, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Bulgaria, Portugal, Latvia, Canada, Hungary, Arge... and more
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Regeneron Pharmaceuticals
Bayer

Completed

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
Bayer

Completed

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice (MAIA)

Retinal Disease

Mexico
Regeneron Pharmaceuticals
Bayer

Completed

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) (VIEW1)

Macular Degeneration

United States, Canada
Bayer
Regeneron Pharmaceuticals

Completed

Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema (APOLLON)

Diabetic Retinopathy

France
Bayer

Completed

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD). (BELUGA)

Neovascular Age-related Macular Degeneration

Belgium
Bayer

Completed

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America (AQUILA)

Macular Degeneration

Mexico, Argentina, Colombia, Costa Rica
Bayer

Completed

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Macular Degeneration

Spain, Switzerland, Portugal, France, Canada, United Kingdom, Austria, Slovakia, Germany, Hungary, Italy, Lithuania, Czechia, Poland
Bayer

Completed

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies (GALAXY)

Macular Degeneration

Germany
Bayer
Regeneron Pharmaceuticals

Completed

Study for Collection of Aflibercept Data in Routine Practice (CODEX)

Eye Diseases

France
Bayer
Regeneron Pharmaceuticals

Completed

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO) (JPMS-CRVO)

Retinal Vein Occlusion

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Diabetic Macular Edema (DME) | Age-related Macular Degeneration (AMD) | Central Retinal Vein Occlusion (CRVO)

Canada
Bayer

Completed

Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece (PERSEUS-GR)

Macular Degeneration | Choroidal Neovascularization

Greece
Bayer

Completed

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME) (VIOLET)

Macular Edema

Spain, Canada, Switzerland, Portugal, Austria, Poland, Slovakia, United Kingdom, Germany, Hungary, Italy, France, Lithuania, Czechia
Bayer
Regeneron Pharmaceuticals

Completed

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Choroidal Neovascularization

Japan
Bayer
Regeneron Pharmaceuticals

Completed

To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada. (PEGASUS)

Wet Macular Degeneration

Canada
Bayer
Regeneron Pharmaceuticals

Completed

EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan

Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration (PERSEUS)

Wet Age-related Macular Degeneration

Germany
Bayer
Regeneron Pharmaceuticals

Completed

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration (ALTAIR)

Wet Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Eylea Post Marketing Surveillance(PMS)

Macular Degeneration

Korea, Republic of
Bayer
Regeneron Pharmaceuticals

Completed

Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy (PERSEUS-IT)

Wet Macular Degeneration

Italy
Bayer
Regeneron Pharmaceuticals

Completed

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD (RAINBOW)

Wet Macular Degeneration

France
Bayer

Completed

A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV) (REALM)

Myopic Choroidal Neovascularization

Canada
Bayer
Regeneron Pharmaceuticals

Completed

EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD) (REALE)

Macular Degeneration

Spain
Bayer

Completed

Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. (AQUA)

Macular Edema

Spain, Canada, Switzerland, Portugal, Austria, Poland, Slovakia, United Kingdom, France, Czechia, Germany, Hungary, Italy, Lithuania
Bayer
RTI Health Solutions

Completed

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

Macular Degeneration

France, Germany, Spain, Italy, United Kingdom
Bayer
Regeneron Pharmaceuticals

Completed

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

Wet Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye (ARIES)

Macular Degeneration

Spain, Hungary, United Kingdom, Australia, Italy, Canada, France, Germany
Bayer
Regeneron Pharmaceuticals

Completed

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)

Macular Degeneration

Belgium, Israel, Italy, Spain, Korea, Republic of, Switzerland, Germany, Portugal, Japan, France, Australia, Netherlands, India, Austria, Brazil, Poland, United Kingdom, Singapore, Hungary, Latvia, Mexico, Czech Republic, Colombia, Ar... and more
Bayer

Active, not recruiting

A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema (VISION-AF)

Diabetic Macular Edema

India
Bayer
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement (VIVID EAST)

Macular Edema

China, Hong Kong, Korea, Republic of, Russian Federation
Bayer
Regeneron Pharmaceuticals

Completed

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) (GALILEO)

Retinal Vein Occlusion

Italy, Korea, Republic of, France, Germany, Australia, Austria, Singapore, Hungary, Latvia, Japan
Regeneron Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (BUTTERFLEYE)

Retinopathy of Prematurity

United States, Bulgaria, Hungary, Russian Federation, Thailand, Turkey, Colombia, Czechia, Korea, Republic of, Romania, Slovakia, Taiwan, Vietnam
Regeneron Pharmaceuticals
Bayer

Completed

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

United States, Canada
Bayer
Regeneron Pharmaceuticals

Completed

Aflibercept in Polypoidal Choroidal Vasculopathy (PLANET)

Neovascular Macular Degeneration

Taiwan, Hong Kong, Korea, Republic of, Japan, Singapore, Australia, Hungary, Germany
Bayer
Regeneron Pharmaceuticals

Completed

VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

Macular Degeneration

China
Regeneron Pharmaceuticals
Bayer

Completed

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact (DA VINCI)

Diabetic Macular Edema

United States, Austria, Canada
Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, United Kingdom, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan
Bayer
Regeneron Pharmaceuticals

Completed

Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema) (VIVID-Japan)

Macular Edema

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Intravitreal Aflibercept Injection in Vision Impairment Due to DME (VIVID-DME)

Diabetes Mellitus | Macular Edema

France, Japan, Australia, Austria, Poland, Czechia, Denmark, Germany, Hungary, Italy, Spain
Bayer
Regeneron Pharmaceuticals

Completed

VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) (Myrror)

Myopia, Pathological

Japan, Taiwan, Hong Kong, Korea, Republic of, Singapore
Pusan National University Hospital
Novartis

Unknown

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) (VIBIM)

Macular Edema, Diabetic

Korea, Republic of
Northern California Retina Vitreous Associates
Regeneron Pharmaceuticals

Completed

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions (NEWTON)

Macular Edema With Central Retinal Vein Occlusions

United States
Yeungnam University College of Medicine

Unknown

Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion

Branch Retinal Vein Occlusion With Macular Edema

Korea, Republic of
Washington University School of Medicine
Regeneron Pharmaceuticals

Completed

Intravitreal Aflibercept Injection for Radiation Retinopathy

Macular Edema | Radiation Retinopathy

United States
Pusan National University Hospital
Bayer

Completed

Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy (VAULT)

Polypoidal Choroidal Vasculopathy | Exudative Age-related Macular Degeneration

Korea, Republic of
Tennessee Retina
Regeneron Pharmaceuticals

Unknown

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept (TRISTAR)

Neovascular Age-related Macular Degeneration

United States

3

Subscribe